Hemlibra Safely Prevents Bleeds in Hemophilia A Patients Over Long Term, Trial Data Show
Hemlibra (emicizumab) continues to safely and effectively prevent bleedings in children and adults with hemophilia A, regardless of developing…
Articles by Marta Figueiredo, PhD
Adynovate Prophylaxis Continues to Show Promise in Severe Hemophilia A, Trials’ Data Show
Prophylactic (preventive) treatment with Adynovate safely and effectively lowers the number of bleedings, including those in target joints, in…
Hemlibra Safely Treats Children With Severe Hemophilia A, Real-Life Study Finds
Prophylactic (preventive) treatment with Hemlibra (emicizumab) safely and effectively lowers bleeding rates in children and adolescents with severe…
Investigational Gene Therapy Results in Huge Drop in Bleeding Rates and Factor VIII Usage, Updated Data Show
Valoctocogene roxaparvovec, BioMarin Pharmaceutical‘s investigational gene therapy, results in a more than 90% drop in annual bleeding rates and…
BioMarin’s Gene Therapy for Hemophilia A Continues to Prevent Bleeds After Four Years, Trial Shows
BioMarin Pharmaceuticals’ investigational gene therapy valoctocogene roxaparvovec continues to safely and effectively prevent bleeding episodes and the need for…
Novo Nordisk Pauses 3 Clinical Trials of Concizumab Amid Safety Concerns
Novo Nordisk has paused three clinical trials evaluating concizumab, its experimental treatment candidate for hemophilia A and B,…
Researchers Develop Faster, Less Expensive, Non-invasive Method for Hemophilia A Prenatal Diagnosis
Researchers have developed a faster, less expensive, reliable method for non-invasive prenatal diagnosis (NIPD) of hemophilia A. Future, larger…
Study Links Specific Genetic Changes to Development of Factor IX Inhibitors in Children With Severe Hemophilia B
Specific genetic changes may account for a larger proportion than previously thought of children with severe hemophilia B who…
ASC Therapeutics Partners with Vigene for Manufacturing Support for Hemophilia A Gene Therapy Program
ASC Therapeutics is partnering with Vigene Biosciences to support the manufacturing process of its current and future…
BioMarin’s Gene Therapy, Found to Reduce Bleeding Events in Hemophilia A, Submitted for U.S. Approval
BioMarin Pharmaceuticals’ investigational gene therapy valoctocogene roxaparvovec safely and significantly reduced bleeding events — including in target joints —…